循环miR-101-3p在妊娠期糖尿病诊断中的作用研究

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (4209 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the differential expression of circulating miRNAs between healthy women and women with gestational diabetes mellitus (GDM), and to identify potential molecular markers related to GDM. Methods Plasma samples were taken from 53 pregnant women with GDM and 30 normal pregnant women with matched age and gestational weeks in Northwest Women's and Children's Hospital from January 2020 to June 2022. The miRNA high-throughput sequencing was used to screen circulating miRNAs related to GDM. Real-time quantitative PCR (RT-qPCR) was used to verify the differentially expressed candidate miRNAs identified from the mirna analysis experiment. Evaluating the expression level of circulating miR-101-3p by using receiver operating characteristic (ROC) curve to predict the value of GDM. Serum hs-CRP and TNF-α levels were measured by enzyme-linked immunosorbent assay. Results Compared with the healthy control group, pregnant women in GDM group had higher levels of triglyceride, hs-CRP, TNF-α and lower levels of HDL-C. Among the 2549 plasma mirnas detected, 267 mirnas showed 2 times or more difference in expression between the two groups. Enrichment of KEGG pathway revealed that miR-101-3p may be involved in glucose, inflammation regulation and lipid metabolism. PCR analysis showed that the plasma miR-101-3p of GDM pregnant women was significantly down-regulated compared with healthy subjects. ROC analysis showed that the sensitivity, specificity and AUC of miR-101-3p in distinguishing healthy control group from GDM group were 0.852, 0.737 and 0.845, respectively. Correlation analysis showed that the expression of plasma miR-101-3p was negatively correlated with blood glucose level, hs-CRP and TNF-α (r=-0.649, -0.602 and -0.735, all P<0.001). Conclusions MiR-101-3p may be involved in insulin resistance and the regulation of inflammatory factors in GDM patients.

Key words： gestational diabetes insulin resistance miRNAs inflammatory factor

Received: 30 November 2022

PACS:

R714.256

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Meng
	WANG Jianying
	JI Ting
	JIA Fei
	LIU Jing

Cite this article:

JIA Meng,WANG Jianying,JI Ting等. Study on the role of circulating miR-101-3p in the diagnosis of gestational diabetes mellitus[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 38-42.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I3/38

[1] 凌思思, 徐琦, 郑小冬, 等. 妊娠早期炎症因子与妊娠期糖尿病发生的相关性初步探讨[J]. 中华妇产科杂志, 2020, 55(5): 333-337.
[2] Jowell A R, Sarma A A, Gulati M, et al.Interventions to mitigate risk of cardiovascular disease after adverse pregnancy outcomes: a review[J]. JAMA Cardiol, 2022, 7(3): 346-355.
[3] 马玉着, 陈素玉, 刘昱婕. 妊娠期糖尿病患者血清miR-15a表达水平及其与母婴不良结局的关系[J]. 安徽医科大学学报, 2022, 57(4): 650-654.
[4] Masete M, Dias S, Malaza N, et al.A big role for microRNAs in gestational diabetes mellitus[J]. Front Endocrinol, 2022, 13: 892587.
[5] Tagoma A, Alnek K, Kirss A, et al.MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes[J]. Gene, 2018, 672: 137-142.
[6] Landrier J F, Derghal A, Mounien L.MicroRNAs in obesity and related metabolic disorders[J]. Cells, 2019, 8(8): 859.
[7] Hocaoglu M, Demirer S, Senturk H, et al.Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus[J]. Pregnancy Hypertens, 2019, 17: 5-11.
[8] Gillet V, Ouellet A, Stepanov Y, et al.miRNA profiles in extracellular vesicles from serum early in pregnancies complicated by gestational diabetes mellitus[J]. J Clin Endocrinol Metab, 2019, 104(11): 5157-5169.
[9] Zhang L, Li K, Tian S, et al.Down-regulation of microRNA-30 d-5p is associated with gestational diabetes mellitus by targeting RAB8A[J]. J Diabetes Complications, 2021, 35(8): 107959.
[10] Meroni M, Longo M, Erconi V, et al.mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance[J]. Nutrients, 2019, 11(11): 2597.
[11] Santos A S, Cunha Neto E, Fukui R T, et al.Increased expression of circulating microRNA 101-3p in type 1 diabetes patients: new insights into miRNA-regulated pathophysiological pathways for type 1 diabetes[J]. Front Immunol, 2019, 10: 1637.
[12] Song L, Feng S, Yu H, et al.Dexmedetomidine Protects Against Kidney Fibrosis in Diabetic Mice by Targeting miR-101-3p-Mediated EndMT[J]. Dose Response, 2022, 20(1): 15593258221083486.
[13] Zhao X, Su F, Kong F, et al.miR-101-3p contributes to the progression of preeclampsia by suppressing WDR5-mediated proliferation and invasion of trophoblast[J]. J Obstet Gynaecol Res, 2023, 49(1): 141-153.
[14] Liu W, Huang Z, Tang S, et al.Changes of serum sex hormone-binding globulin, homocysteine, and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus[J]. Gynecol Obstet Invest, 2021, 86(1): 193-199.
[15] Hu J, Gillies C L, Lin S, et al.Association of maternal lipid profile and gestational diabetes mellitus: A systematic review and meta-analysis of 292 studies and 97, 880 women[J]. EClinicalMedicine, 2021, 34: 100830.
[16] Zhao X, Li S, Wang Z, et al.miR-101-3p negatively regulates inflammation in systemic lupus erythematosus via MAPK1 targeting and inhibition of the NF-κB pathway[J]. Mol Med Rep, 2021, 23(5): 359.